Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/ CFD/ CMD1/162/2019 dated December 24, 2019, a statement ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shree Pacetronix Limited has confirmed no deviation or variation in the utilization of funds raised through a preferential issue. The company raised Rs. 152.18 lakh total by allotting 75,150 equity shares and 225,450 fully convertible warrants to promoters in November 2025 at Rs. 81 per share. In March 2026, the company converted 75,150 Series A warrants into equity shares upon receiving the balance 75% payment. The funds have been deployed for capital expenditure to set up and upgrade manufacturing facilities for pacemaker production (including automation and cleanroom technology) and general corporate purposes. The Audit Committee reviewed and the Board took the statement on record.
No deviation in fund utilization is a positive signal for shareholders as it confirms the company is using the raised capital as committed. The ongoing investment in manufacturing facilities for pacemaker production may support future revenue growth.